- Home
- PERI vs ATXS Comparison
PERI vs ATXS Comparison
Compare PERI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- ATXS
- Stock Information
- Founded
- PERI 1999
- ATXS 2008
- Country
- PERI Israel
- ATXS United States
- Employees
- PERI N/A
- ATXS N/A
- Industry
- PERI EDP Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- PERI Technology
- ATXS Health Care
- Exchange
- PERI Nasdaq
- ATXS Nasdaq
- Market Cap
- PERI 412.5M
- ATXS 424.4M
- IPO Year
- PERI 2006
- ATXS 2015
- Fundamental
- Price
- PERI $9.62
- ATXS $11.92
- Analyst Decision
- PERI Buy
- ATXS Buy
- Analyst Count
- PERI 4
- ATXS 7
- Target Price
- PERI $11.83
- ATXS $28.33
- AVG Volume (30 Days)
- PERI 220.6K
- ATXS 2.8M
- Earning Date
- PERI 11-05-2025
- ATXS 11-12-2025
- Dividend Yield
- PERI N/A
- ATXS N/A
- EPS Growth
- PERI N/A
- ATXS N/A
- EPS
- PERI N/A
- ATXS N/A
- Revenue
- PERI $424,098,000.00
- ATXS N/A
- Revenue This Year
- PERI N/A
- ATXS N/A
- Revenue Next Year
- PERI $11.40
- ATXS N/A
- P/E Ratio
- PERI N/A
- ATXS N/A
- Revenue Growth
- PERI N/A
- ATXS N/A
- 52 Week Low
- PERI $7.00
- ATXS $3.56
- 52 Week High
- PERI $11.79
- ATXS $12.52
- Technical
- Relative Strength Index (RSI)
- PERI 51.75
- ATXS 84.30
- Support Level
- PERI $9.47
- ATXS $7.85
- Resistance Level
- PERI $10.40
- ATXS $12.17
- Average True Range (ATR)
- PERI 0.29
- ATXS 0.43
- MACD
- PERI 0.01
- ATXS 0.41
- Stochastic Oscillator
- PERI 38.40
- ATXS 94.67
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.